Gsk PLC 6-K Filing
Ticker: GSK · Form: 6-K · Filed: Apr 1, 2026 · CIK: 0001131399
Sentiment: neutral
Filing Stats: 908 words · 4 min read · ~3 pages · Grade level 11.3 · Accepted 2026-04-01 06:37:51
Key Financial Figures
- $2.125 b — shares to Shionogi for consideration of $2.125 bn and cancelled Pfizer's holding in ViiV
- $1.875 b — ing in ViiV Healthcare. Pfizer received $1.875 bn and GSK received a special dividend of
- $0.250 b — and GSK received a special dividend of $0.250 bn (paid in GBP).   Financial Co
Filing Documents
- a8796y.htm (6-K) — 35KB
- 0001654954-26-003119.txt ( ) — 36KB
Forward-Looking Statements
Forward-Looking Statements This announcement contains forward-looking statements. These currently available and assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. These risks and uncertainties particularly apply with respect to transaction-related forward-looking to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.   GSK enquiries       Media: Tim Foley +44 (0) 20 8047 5502 (London)   Sarah Clements +44 (0) 20 8047 5502 (London)   Kathleen Quinn +1 202 603 5003 (Washington DC)   Alison Hunt +1 540 742 3391 (Washington DC)         Investor Relations: Constantin Fest +44 (0) 7831 826525 (London)   James Dodwell +44 (0) 20 8047 2406 (London)   Mick Readey +44 (0) 7990 339653 (London)   Steph Mountifield +44 (0) 7796 707505 (London)   Sam Piper +44 (0) 7824 525779 (London)   Jeff McLaughlin +1 215 751 7002 (Philadelphia)   Frannie DeFranco +1 215 751 3126 (Philadelphia)   Shionogi enquiries Website Inquiry Form:   https://www.shionogi.com/global/en/contact.html     Cautionary statement regarding forward-looking GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.     Registered in England & Wales:   No. 3888792  
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: April 01, 2026         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc